Analytical and Clinical Validation of the Oncomine Dx Target Test to Assess HER2 Mutation Status in Tumor Tissue Samples From Patients With Non-Small Cell Lung Cancer Treated With Trastuzumab Deruxtecan in the DESTINY-Lung01 and DESTINY-Lung02 Studies.

doi:10.5858/arpa.2024-0014-OA

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Analytical and Clinical Validation of the Oncomine Dx Target Test to Assess HER2 Mutation Status in Tumor Tissue Samples From Patients With Non-Small Cell Lung Cancer Treated With Trastuzumab Deruxtecan in the DESTINY-Lung01 and DESTINY-Lung02 Studies.

Archives of pathology & laboratory medicine - 1 Jun 2025

Qi Zhenhao, Ha Thomas, Feng Wenqin, Karnoub Maha, Pereira Kaline, Shiga Ryota, Smit Egbert F, Goto Yasushi, De Langen Adrianus Johannes, Goto Koichi, Velasco Roth Anne Marie, Khambata-Ford Shirin

Abstract excerpt

CONTEXT.—: Trastuzumab deruxtecan (T-DXd), a human epidermal growth factor receptor 2 (HER2)-targeted therapy, has demonstrated durable anticancer activity in patients with advanced, metastatic HER2 (also known as ERBB2)-mutant (HER2m) non-small cell lung cancer (NSCLC) who have limited treatment options and poor prognosis. OBJECTIVE.—: To analytically validate and assess the clinical utility of the Oncomine Dx...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Camptothecin

Share to Carcinoma, Non-Small-Cell Lung

Share to Erb-b2 Receptor Tyrosine Kinases

Share to Immunoconjugates

Share to Lung Neoplasms

Share to Trastuzumab

Source

Open in PubMed

Identifiers

PMID: 39299708
DOI: 10.5858/arpa.2024-0014-OA

Genes

ERBB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analytical and Clinical Validation of the Oncomine Dx Target Test to Assess HER2 Mutation Status in Tumor Tissue Samples From Patients With Non-Small Cell Lung Cancer Treated With Trastuzumab Deruxtecan in the DESTINY-Lung01 and DESTINY-Lung02 Studies.PMID 39299708Read ↗

Clinical utility of the Oncomine Dx Target Test multi-CDx system and the possibility of utilizing those original sequence data.Semantic proximity Read ↗

Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC.Semantic proximity Read ↗

Simulation analysis of EGFR mutation detection: Oncomine Dx target test and AmoyDx panel impact on lung cancer treatment decisions.Semantic proximity Read ↗

Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer: a plain language summary of the DESTINY-Lung01 study.Semantic proximity Read ↗

Validation and Prospective Testing of a High Sensitivity, Quantitative Analytic Assay for HER2 on Histopathology SlidesSemantic proximity Read ↗

Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study.Semantic proximity Read ↗

Comparison of diagnostic performance between Oncomine Dx target test and AmoyDx panel for detecting actionable mutations in lung cancer.Semantic proximity Read ↗

Evaluation of appropriate conditions for Oncomine DxTT testing of FFPE specimens for driver gene alterations in non-small cell lung cancer.Semantic proximity Read ↗

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort.Semantic proximity Read ↗

Trastuzumab Deruxtecan Combination Strongly Enhances Responses and Overcomes Sotorasib Resistance in <i>KRAS</i> <sup>G12C</sup> -Mutant NSCLCSemantic proximity Read ↗

[Trastuzumab Deruxtecan for EGFR-mutant Lung Adenocarcinoma with Acquired High-level HER2 Amplification: A Case Report].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.